Navigation Links
New study suggests promising drug combinations for sleeping sickness

Results from a clinical trial evaluating new drug combinations for sleeping sickness, carried out by the international humanitarian medical aid agency Medecins Sans Frontieres (MSF), and its research arm, Epicentre, have now been published in the journal PLoS Clinical Trials.

African trypanosomiasis, or sleeping sickness affects many tens of thousands of people each year in sub-Saharan Africa and is a serious disease for which there are few treatment options. The most commonly used drug, Melarsoprol, is highly toxic. MSF and Epicentre jointly carried out a trial that started in 2001 in Uganda to evaluate the efficacy and safety of three drug combinations for this disease. The aim was to find out if any of these combinations would provide a viable treatment option for patients with second-stage sleeping sickness, where infection has reached the brain and prognosis is normally very poor. In the trial the drug combinations compared were melarsoprol-nifurtimox, melarsoprol-eflornithine, and nifurtimox-eflornithine. However, once 54 patients had been recruited (435 were planned), it was obvious that the death rate was much higher amongst individuals receiving one of the combinations, so the trial was stopped.

In the trial, the cure rate for nifurtimox-eflornithine was over twice that for melarsoprol-nifurtimox and substantially higher than that for melarsoprol-eflornithine. The rates of adverse events were also lower for patients treated with nifurtimox-eflornithine. These findings are encouraging and suggest that the nifurtimox-eflornithine combination has potential as a future therapy for second-stage African trypanosomiasis, and should be evaluated further in clinical trials.
'"/>

Source:Public Library of Science


Page: 1

Related biology news :

1. Bioartificial kidney under study at MCG
2. W.M. Keck Foundation funds study of friendly microbes
3. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
4. Genome-wide mouse study yields link to human leukemia
5. Clam embryo study shows pollutant mixture adversely affects nerve cell development
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Same mutation aided evolution in many fish species, Stanford study finds
8. Sequencing of marine bacterium will help study of cell communication
9. Genetically modified rice in China benefits farmers health, study finds
10. A new study examines how shared pathogens affect host populations
11. NYU study reveals how brains immune system fights viral encephalitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/9/2016)... -- Perkotek an innovation leader in attendance control systems is proud to announce the introduction ... to make sure the right employees are actually signing in, and to even control ... ... ... ...
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... PRUSSIA, PA (PRWEB) , ... December 01, 2016 , ... ... is through industry-wide collaboration, standardization and a beautiful technology experience. All three tenets were ... more than 100 clinical trial leaders from over 40 sponsor, CRO and site organizations ...
(Date:12/2/2016)... Dec. 1, 2016   SurePure, Inc. (OTCQB: ... that the Company has concluded an agreement with Tamarack ... a 90-day period to acquire units of the Company,s ... USD 3.7 million.  Concurrently with the ... under which Tamarack will seek regulatory approvals in ...
(Date:11/30/2016)... 30, 2016  GenomOncology today announced the appointment of ... Affairs.  Dr. Coleman will oversee clinical content ... knowledge-enabled platform. The GenomOncology software suite empowers molecular pathologists with ... and clinical decision support, from quality control through reporting. ... , , ...
(Date:11/30/2016)... , Nov. 30, 2016  The Allen Institute ... Collection: the first publicly available collection of gene ... that target key cellular structures with unprecedented clarity. ... these powerful tools are a crucial first step ... better understand what makes human cells healthy and ...
Breaking Biology Technology: